Matt Bush represents life sciences and technology companies, ranging from startups to publicly held corporations. He is a sought-after advisor in transactional matters ranging from company formation through maturing growth and exit strategy, which includes day-to-day guidance, venture financings, initial public offerings, mergers and acquisitions, SEC disclosures, corporate governance, and aftermarket capital raising. Mr. Bush is the former Chair of the San Diego office’s Corporate Department.
Prior to entering law school, Mr. Bush was a manager with Accenture, where he assisted clients with business process reengineering and enterprise software implementation.
Mr. Bush’s selected IPO, equity offering, and public company representation experience includes the following:
Representing the companies: Mineralys, HilleVax, Prometheus Biosciences, Icosavax, Erasca, Tyra Biosciences, Avidity Biosciences, Phathom Pharmaceuticals, Gossamer Bio, Cubic Corporation, Crinetics, Ignyta, Zogenix, Airgain, Ballast Point Brewing & Spirits, Exagen, Evoke Pharma, Conatus Pharmaceuticals, BIND Therapeutics, Orexigen, Cadence, Somaxon, and Santarus
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.